Oxaliplatin 01
Chemical structure of oxaliplatin showing the platinum atom coordinated with cyclohexane-1,2-diamine and oxalate ligands.*
Oxaliplatin Injection, Powder, Lyophilized, For Solution
Product Images NDC 67184-0502
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Oxaliplatin (NDC 67184-0502). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Qilu Pharmaceutical Co., Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Oxaliplatin 02
A survival analysis Kaplan-Meier chart showing disease-free survival (DFS) probability over time in months. The chart compares two treatment arms, FOLFOX4 and LV5FU2, with corresponding event numbers and hazard ratio data. Numbers of patients at risk are listed below the time axis for each arm.*
Oxaliplatin 03
A Kaplan-Meier survival curve chart illustrating Disease-Free Survival (DFS) probability over time in months (0-72) comparing two treatment arms: FOLFOX4-DUKES C (solid line) and LV5FU2-DUKES C (dashed line). The chart includes a hazard ratio of 0.78 with 95% confidence interval 0.65 to 0.93, and a Logrank test p-value of 0.005, indicating statistical comparison between groups at Stage III disease.*
Oxaliplatin 04
A survival curve chart showing the percentage of patients surviving over 24 months for three treatment groups: Oxaliplatin for Injection plus 5-FU/LV, Oxaliplatin for Injection plus Irinotecan, and Irinotecan plus 5-FU/LV. The chart includes median survival times of 19.4, 17.6, and 14.6 months respectively, with a log rank test p-value less than 0.0001 comparing Oxaliplatin plus 5-FU/LV to Irinotecan plus 5-FU/LV.*
Oxaliplatin 05
Label for Oxaliplatin For Injection, USP 50 mg/vial, a single-dose vial containing sterile lyophilized powder for intravenous use. The label includes storage instructions, a warning against reconstituting with sodium chloride solutions, and details on manufacturing and distribution by Qilu Pharmaceutical Co., Ltd. The product is designated as a cytotoxic agent and prescription-only.*
Oxaliplatin 06
Carton label for Oxaliplatin 50 mg/vial injection, powder, lyophilized for solution. The label states it is for intravenous use only, with dosage strength prominently displayed in blue. It includes directions about reconstitution, storage instructions, and a barcode. Labeler is Qilu Pharmaceutical Co., Ltd., China.*
Oxaliplatin 07
Label for Oxaliplatin For Injection, USP 100 mg/vial, single dose vial. The label indicates the product is a sterile lyophilized powder for intravenous use only, cytotoxic agent, preservative free. It includes storage instructions, dosage form, and manufacturer Qilu Pharmaceutical Co., Ltd., Haikou, Hainan, China. The label also shows a barcode and notes that the vial must be reconstituted and diluted before use.*
Oxaliplatin 08
Carton label for Oxaliplatin For Injection, USP 100 mg/vial, a cytotoxic agent for intravenous use only. The lyophilized powder requires reconstitution before use and must not be mixed with sodium chloride or chloride-containing solutions. The label includes storage instructions, distributor and manufacturer details (Qilu Pharmaceutical Co., Ltd.), and spaces for batch number and expiration date.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
